The recent turmoil within the FDA, marked by a significant staff exodus and low morale, has raised alarms among public health officials and inspectors. Reports indicate that layoffs at the agency could impact the safety of medications produced at foreign factories. This unrest comes amid criticism from figures like RFK Jr., who claims that public health agencies are heading downhill under current leadership. The situation reflects growing frustrations among FDA staff, with many feeling fed-up and demoralized. Additionally, the broader implications of these challenges are being discussed in relation to a potential U.S.-Swiss trade deal on pharmaceutical levies.